Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| Mineralys Therapeutics, Inc.MLYS · Entity 4432 | Director | February 19, 2026 | February 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 50,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 50,000 · Balance 50,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
Mineralys Therapeutics, Inc.
Report date February 19, 2026 · Filed February 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,200 |
Reported balance
After 2026-02-19 transaction · row 1
1 source rowRow 1 · 2026-02-19 · Grant · Acquired 6,200 · Balance 6,200 F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.06 · Expires 2036-02-19 | Direct | 8,300 |
Reported balance
After 2026-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-19 · Grant · Acquired 8,300 · Balance 8,300 F2: The stock option vests in 12 substantially equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.
F2: The stock option vests in 12 substantially equal monthly installments following the date of grant.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMICUS THERAPEUTICS, INC.
Report date April 27, 2026 · Filed April 27, 2026
Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 1
1 source rowRow 1 · 2026-04-27 · Disposition to issuer · Disposed 142,564 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 122,150 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-27 · Disposition to issuer · Disposed 16,236 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-27 · Disposition to issuer · Disposed 19,473 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05 | Direct | 0 |
Reported balance
After 2026-04-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 122,150 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3: Each Option was fully vested.
F4: Each Option vested in full in connection with consummation of the Merger.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 23,447 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $210.36 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 551 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $183.62 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 1,750 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 1,598 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof
IVERIC bio, Inc.
Report date July 11, 2023 · Filed July 13, 2023
Section 16 reporting ended · disclosed 2023-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 1
1 source rowRow 1 · 2023-07-11 · Disposition to issuer · Disposed 239,275 · Balance 0 F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-11 · Disposition to issuer · Disposed 23,750 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-11 · Disposition to issuer · Disposed 73,315 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-11 · Disposition to issuer · Disposed 94,500 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-11 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.27 · Expires 2023-10-23 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-07-11 · Disposition to issuer · Disposed 6,949 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.00 · Expires 2024-05-20 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-07-11 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.30 · Expires 2025-06-01 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-07-11 · Disposition to issuer · Disposed 7,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.90 · Expires 2026-03-31 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-07-11 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2027-01-29 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-07-11 · Disposition to issuer · Disposed 260,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2027-12-18 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-07-11 · Disposition to issuer · Disposed 325,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2028-12-11 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-07-11 · Disposition to issuer · Disposed 133,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2029-12-08 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-07-11 · Disposition to issuer · Disposed 190,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.50 · Expires 2030-12-17 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-07-11 · Disposition to issuer · Disposed 293,150 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.83 · Expires 2031-12-16 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2023-07-11 · Disposition to issuer · Disposed 252,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.57 · Expires 2032-12-19 | Direct | 0 |
Reported balance
After 2023-07-11 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2023-07-11 · Disposition to issuer · Disposed 300,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes.
F2: Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-031960 · tv524026_4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,086 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| May 10, 2019 Filed May 13, 2019 16:09 UTC | IVERIC bio, Inc. ISEE · Entity 111416 | PurchaseCommon Stock | 25,000 | $1.48 | $37,000.00 |
DisclosureSEC source: 0001104659-19-028906 · a4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,105 F1 · price: These shares were acquired in multiple transactions on May 10, 2019 at actual sales prices ranging from $1.47 to $1.48 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares acquired at each separate price. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 18:11 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 6,914 | $1.43 | $9,887.02 |
DisclosureSEC source: 0001104659-19-019738 · a4.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,105 F3 · shares: Represents shares automatically sold pursuant to the prespecified terms of the reporting person's Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on April 1, 2019. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:11 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-019738 · a4.xml · derivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On April 1, 2016, the reporting person was granted an award of 75,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:11 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-019738 · a4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · balance_after: This total includes 3,078 shares acquired by the reporting person on September 15, 2018 under the issuer's 2016 Employee Stock Purchase Plan and 4,734 shares acquired by the reporting person on March 15, 2019 under the issuer's 2016 Employee Stock Purchase Plan. This total has also been increased by 50 shares to correct a scrivener's error in the amount of securities reported as beneficially owned by the reporting person on the Form 4 filed on April 4, 2017. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantRestricted Stock Units · Derivative | 91,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-073130 · a4.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,800 Underlying: Common Stock · 91,800 shares Expires 2028-12-11 F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F3 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 17:13 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 183,500 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001104659-18-073130 · a4.xml · derivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,500 Underlying: Common Stock · 183,500 shares Expires 2028-12-11 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, each of these stock option awards will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the "Performance Condition"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to "double-trigger" acceleration of vesting upon termination of employment following a change in control of the Registrant. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:04 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,748 | $0.00 Strike: $85.12 | $0.00 |
DisclosureSEC source: 0001144204-18-035423 · tv496990_4.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,748 Underlying: Common Stock · 2,748 shares Expires 2028-06-20 F2 · derivative.exercise_date: All of the shares subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:04 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-035423 · tv496990_4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,516 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 8,912 | $0.00 Strike: $16.23 | $0.00 |
DisclosureSEC source: 0001209191-18-037000 · doc4.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,912 Underlying: Common Stock · 8,912 shares Expires 2028-06-07 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 20:46 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 3,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037000 · doc4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,895 F1 · shares: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common stock. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 19:06 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 6,838 | $2.69 | $18,394.22 |
DisclosureSEC source: 0001104659-18-022242 · a4.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,407 F2 · shares: Represents shares automatically sold pursuant to the pre-specified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on April 1, 2018. F3 · price: These shares were disposed of in multiple transactions on April 2, 2018 at actual sales prices ranging from $2.67 to $2.71 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 19:06 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-022242 · a4.xml · derivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 18,750 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On April 1, 2016, the reporting person was granted an award of 75,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 19:06 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-022242 · a4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 17:01 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 8,089 | $3.19 | $25,803.91 |
DisclosureSEC source: 0001104659-18-000567 · a4.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,495 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on December 29, 2017. F3 · price: These shares were disposed of in multiple transactions on January 2, 2018 at actual sales prices ranging from $3.10 to $3.25 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 17:01 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 20,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-000567 · a4.xml · derivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,420 shares Expires 2027-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 17, 2017, the reporting person was granted an award of 40,840 restricted stock units, which vested with respect to 50% of the shares subject to the award on each of June 30, 2017 and December 29, 2017, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 17:01 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 20,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-18-000567 · a4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| December 19, 2017 Filed Dec 21, 2017 17:08 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001104659-17-074632 · a4.xml · derivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, each of these stock option awards will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
| July 05, 2017 Filed Jul 5, 2017 18:31 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 7,828 | $2.58 | $20,196.24 |
DisclosureSEC source: 0001104659-17-043657 · a4.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,164 F2 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on June 30, 2017. F3 · price: These shares were disposed of in multiple transactions on July 5, 2017 at actual sales prices ranging from $2.55 to $2.64 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:31 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 20,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-043657 · a4.xml · derivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,420 Underlying: Common Stock · 20,420 shares Expires 2027-01-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F4 · derivative.exercise_date: On January 17, 2017, the reporting person was granted an award of 40,840 restricted stock units, which vests with respect to 50% of the shares subject to the award on each of June 30, 2017 and December 29, 2017, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:31 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 20,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-043657 · a4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,992 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:04 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,036 | $0.00 Strike: $122.01 | $0.00 |
DisclosureSEC source: 0001144204-17-035036 · v470077_form4.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036 Underlying: Common Stock · 2,036 shares Expires 2027-06-27 F1 · derivative.exercise_date: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:04 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-035036 · v470077_form4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,729 F1 · shares: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:26 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantStock Options (right to buy) · Derivative | 16,236 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001209191-17-040147 · doc4.xml · derivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,236 Underlying: Common Stock · 16,236 shares Expires 2027-06-13 F1 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2018. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:26 UTC | AMICUS THERAPEUTICS, INC. FOLD · Entity 51196 | GrantCommon Stock | 5,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040147 · doc4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,747 Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 19:10 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 7,388 | $3.56 | $26,301.28 |
DisclosureSEC source: 0001104659-17-021482 · a4.xml · nonDerivative · entry 2 SBLENDORIO GLENN · CIK 0001277478 · President, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,572 F3 · shares: Represents shares automatically sold pursuant to the prespecified terms of the applicable Restricted Stock Unit Agreement to satisfy the reporting person's minimum statutory withholding obligations with respect to the income recognized by the reporting person upon the vesting of the restricted stock units on April 1, 2017. F4 · price: These shares were disposed of in multiple transactions on April 3, 2017 at actual sales prices ranging from $3.55 to $3.59 per share. The price reported reflects the weighted average sale price for the transactions. The reporting person undertakes to provide upon request by the staff of the Securities Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 19:10 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-021482 · a4.xml · derivative · entry 3 SBLENDORIO GLENN · CIK 0001277478 · President, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 18,750 shares Expires 2026-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F5 · derivative.exercise_date: On April 1, 2016, the reporting person was granted an award of 75,000 restricted stock units, which vests with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date, subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 19:10 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | Exercise / conversionCommon Stock | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-021482 · a4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · President, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units. F2 · balance_after: This total includes 210 shares acquired by the reporting person under the issuer's 2016 Employee Stock Purchase Plan on March 15, 2017. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 17:14 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantStock Option (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001104659-17-005850 · a4.xml · derivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · President, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2027-01-29 F1 · derivative.exercise_date: Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, each of these stock option awards will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 17:35 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | GrantRestricted Stock Units · Derivative | 40,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-003126 · a4.xml · derivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · EVP, COO & CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,840 Underlying: Common Stock · 40,840 shares Expires 2027-01-16 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · derivative.exercise_date: Subject to continued employment with the issuer and the other terms and conditions under the issuer's 2013 Stock Incentive Plan and the reporting person's employment agreement, the award of restricted stock units will vest with respect to 50% of the shares subject to the award on each of June 30, 2017 and December 29, 2017. Read SEC document |
| December 22, 2016 Filed Dec 23, 2016 17:05 UTC | IVERIC bio, Inc. OPHT · Entity 111416 | SaleCommon Stock | 1,079 | $4.85 | $5,236.49 |
DisclosureSEC source: 0001104659-16-163792 · a4.xml · nonDerivative · entry 1 SBLENDORIO GLENN · CIK 0001277478 · EVP, COO & CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.